Ingredients Glutathione, Water, Sodium Hyaluronate, Tocopheryl Acetate, Niacinamide, Propanediol, Glycerin, Xanthan Gum, Potassium Sorbate, Citric Acid, Phenoxyethanol, Disodium EDTA
Any doctor administering this treatment off-label is obligated under SMC Ethical Code and Ethical Guidelines to ensure the patient has received a full and transparent account of these risks prior to consent
1 G6PD initiates the first step in the pentose phosphate pathway, reducing NADP into NADPH

GLP-1 gastroparesis affects 4-fold more patients than placebo groups , with non-diabetic users facing 3.33 times higher risk than alternative weight loss treatments Short-acting GLP-1s cause more severe gastric slowing than long-acting versions , delaying emptying by 52 minutes versus 25 minutes respectively Retained gastric contents occur in 13.6% of GLP-1 users versus 2.3% of non-users , creating dangerous aspiration risks during medical procedures Most GLP-1 gastroparesis cases are reversible through tachyphylaxis , with gastric emptying effects diminishing within 4-6 weeks of continuous use Pre-procedural fasting protocols must be extended for GLP-1 users , holding daily medications on procedure day and weekly doses seven days before surgery The condition requires careful differentiation from functional dyspepsia and mechanical obstruction, as proper diagnosis directly impacts treatment outcomes